Global Anti-radiation Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Anti-radiation Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Anti-radiation drugs offer protection against radiation exposure. These drugs include Kl,Prussian Blue, and DTPA (Diethylenetriamine pentaacetate). Anti-radiation medicines help block the absorption and subsequent concentration of radioactive iodine in the thyroid gland. KI must be consumed before or shortly after exposure to radioactive iodine for better results.It is effective only against radioactive iodine and not against other types of radiation. Oxidation of ferrous ferrocyanide salts produces Prussian blue that is used for the treatment of thallium poisoning or radioactive cesium poisoning.
Global Anti-radiation Drugs market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Demand from Acute Radiation Syndrome(ARS) and Cancer Treatment are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Anti-radiation Drugs industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, Anti-radiation Drugs key manufacturers include Amgen, Anbex, BTG International, Cellphire, Chrysalis BioTherapeutics, Darnitsa, Enzychem Lifesciences, Humanetics and Mission Pharmacal, etc. Amgen, Anbex, BTG International are top 3 players and held % sales share in total in 2022.
Anti-radiation Drugs can be divided into Potassium lodide (KI), Prussian Blue, DTPA (Diethylenetriamine Pentaacetate) and Others, etc. Potassium lodide (KI) is the mainstream product in the market, accounting for % sales share globally in 2022.
Anti-radiation Drugs is widely used in various fields, such as Acute Radiation Syndrome(ARS), Cancer Treatment, Radiation Exposure and Others, etc. Acute Radiation Syndrome(ARS) provides greatest supports to the Anti-radiation Drugs industry development. In 2022, global % sales of Anti-radiation Drugs went into Acute Radiation Syndrome(ARS) filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Anti-radiation Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Amgen
Anbex
BTG International
Cellphire
Chrysalis BioTherapeutics
Darnitsa
Enzychem Lifesciences
Humanetics
Mission Pharmacal
Partner Therapeutics
Myelo Therapeutics
Pluri
Segment by Type
Potassium lodide (KI)
Prussian Blue
DTPA (Diethylenetriamine Pentaacetate)
Others
Acute Radiation Syndrome(ARS)
Cancer Treatment
Radiation Exposure
Others
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Anti-radiation Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Anti-radiation Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Anti-radiation Drugs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Anti-radiation Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Anti-radiation Drugs introduction, etc. Anti-radiation Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Anti-radiation Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Global Anti-radiation Drugs market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Demand from Acute Radiation Syndrome(ARS) and Cancer Treatment are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Anti-radiation Drugs industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, Anti-radiation Drugs key manufacturers include Amgen, Anbex, BTG International, Cellphire, Chrysalis BioTherapeutics, Darnitsa, Enzychem Lifesciences, Humanetics and Mission Pharmacal, etc. Amgen, Anbex, BTG International are top 3 players and held % sales share in total in 2022.
Anti-radiation Drugs can be divided into Potassium lodide (KI), Prussian Blue, DTPA (Diethylenetriamine Pentaacetate) and Others, etc. Potassium lodide (KI) is the mainstream product in the market, accounting for % sales share globally in 2022.
Anti-radiation Drugs is widely used in various fields, such as Acute Radiation Syndrome(ARS), Cancer Treatment, Radiation Exposure and Others, etc. Acute Radiation Syndrome(ARS) provides greatest supports to the Anti-radiation Drugs industry development. In 2022, global % sales of Anti-radiation Drugs went into Acute Radiation Syndrome(ARS) filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Anti-radiation Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Amgen
Anbex
BTG International
Cellphire
Chrysalis BioTherapeutics
Darnitsa
Enzychem Lifesciences
Humanetics
Mission Pharmacal
Partner Therapeutics
Myelo Therapeutics
Pluri
Segment by Type
Potassium lodide (KI)
Prussian Blue
DTPA (Diethylenetriamine Pentaacetate)
Others
Segment by Application
Acute Radiation Syndrome(ARS)
Cancer Treatment
Radiation Exposure
Others
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Anti-radiation Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Anti-radiation Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Anti-radiation Drugs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Anti-radiation Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Anti-radiation Drugs introduction, etc. Anti-radiation Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Anti-radiation Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices